Government-Owned Inventions; Availability for Licensing, 40120-40122 [2014-16265]

Download as PDF 40120 Federal Register / Vol. 79, No. 133 / Friday, July 11, 2014 / Notices over other diagnostics including sensitive cancer detection, small sample size (100–200 cells), probes to all genomic regions are available, and it does not require mitotic chromosomes. Additionally, it is applicable to both solid tumors and blood cancers, allows analysis of subpopulations from biopsy, measures metastatic potential of cancer cells, determines tumor type, and can be alternative to or complementary to conventional diagnostics. The prospective exclusive evaluation option license, and a subsequent exclusive commercialization license, may be granted unless the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404 within fifteen (15) days from the date of this published notice. Complete applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive evaluation option license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: July 10, 2014. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–16268 Filed 7–10–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of MolecularBased Cancer Diagnostic and Prognostic AGENCY: National Institutes of Health, HHS. ACTION: Notice. This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Heragen, Inc., which is located in Benicia, California to practice the inventions embodied in the following patent applications: tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: 1. U.S. Provisional Application 61/152,597 filed February 13, 2009 entitled ‘‘MolecularBased Method of Cancer Diagnosis and VerDate Mar<15>2010 20:23 Jul 10, 2014 Jkt 232001 Prognosis’’ (HHS Ref No. E–023–2009/0–US– 01). 2. International Application PCT/US2010/ 024026 filed February 12, 2010 entitled ‘‘Molecular-Based Method of Cancer Diagnosis and Prognosis’’ (HHS Ref No. E– 023–2009/0–PCT–02). 3. U.S. Patent No. 8,715,928 issued May 6, 2014 entitled ‘‘Molecular-Based Method of Cancer Diagnosis and Prognosis’’ (HHS Ref No. E–023–2009/0–US–03). 4. U.S. Patent Application No. 14/215,574, filed March 17, 2014 entitled ‘‘MolecularBased Method of Cancer Diagnosis and Prognosis’’ (HHS Ref No. E–023–2009/0–US– 04). The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to the use of the Licensed Patent Rights to develop FDA approved and/or 510K cleared tests and kits for the diagnosis and prognosis of breast and lung cancer. DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 11, 2014 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Whitney A. Hastings, Ph.D., Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 451– 7337; Facsimile: (301) 402–0220; Email: hastingw@mail.nih.gov. SUPPLEMENTARY INFORMATION: Molecular profiling with high throughput assays has gained utility in the management of select cancer patients and several gene expression-based assays are now marketed for improved prognostic accuracy for patients with cancer. This technology describes a genomics based diagnostic assay for the diagnosis and prognosis of cancer patients. Using a mouse model of breast cancer, the inventors identified a gene expression signature that can predict the outcome for human breast cancer patients with as few as six genes. The gene signature includes a total of 79 cancer survival factor-associated genes and was validated using available genomic test sets that were based on previously conducted human clinical trials. More recently, the six-gene-model was validated for cancers other than breast using multiple, independent, publiclyavailable human lung cancer data sets. In addition to predicting the outcome of cancer patients, this technology could PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 also be used to stratify patients for further therapy and treat patients by administering therapeutic agents that alter the activity of one of the aforementioned cancer survival factorassociated genes. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Any additional applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: July 10, 2014. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–16266 Filed 7–10–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive SUMMARY: E:\FR\FM\11JYN1.SGM 11JYN1 Federal Register / Vol. 79, No. 133 / Friday, July 11, 2014 / Notices tkelley on DSK3SPTVN1PROD with NOTICES Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. Delta Tocopherol for the Treatment of Lysosomal Storage Disorders Description of Technology: Delta Tocopherol is identified as a novel therapeutic to treat lysosomal disorders characterized by defective cellular cholesterol and other lipid trafficking and storage. Currently, there is no treatment for many of Lysosomal Storage Disorders. In some cases, such as Gaucher disease, enzyme replacement therapy and substrate deduction treatment are available with very high cost (over $100,000 per patient per year). NIH investigators have identified an unexpected and previously unrecognized use for delta tocopherol, which is a form of vitamin E, in the treatment of diseases and conditions related to lysosomal storage disorders. Scientists at the National Center for Advancing Translational Sciences, NIH discovered a clear difference between the effects of delta-tocopherol and alpha tocopherol on the cell-based disease models of Niemann Pick C (NPC) disease. They found that while deltatocopherol significantly reduced the cholesterol accumulation in NPC cells and reduced the size of enlarged lysosomes, alpha-tocopherol only showed weak effects in the same cells. The present invention can be used to develop new therapies involving deltatocopherol to treat lysosomal disorders, such as Niemann-Pick type C disease, Mucopolysaccharidoses disorder, and Neuronal Ceroid Lipofuscinoses. This invention provides potential novel methods for the modulation of cholesterol and other lipids’ recycling. It may be also possible to use deltatocopherol for the reduction of the size of enlarged lysosomes caused by accumulation of lipids and macromolecules. Potential Commercial Applications: • Therapeutics for lysosomal disorders • Therapeutics for Niemann-Pick type C disease Competitive Advantages: deltatocopherol is a novel lead compound for drug development to treat a variety of lysosomal storage diseases characterized by lipid/macromolecule accumulation and defective lipid trafficking. Development Stage: • Early-stage • In vitro data available VerDate Mar<15>2010 20:23 Jul 10, 2014 Jkt 232001 Inventors: Wei Zheng et al. (NCATS). Publications: 1. Xu M, et al. delta-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem. 2012 Nov 16;287(47):39349–60. [PMID 23035117] 2. Yu D, et al. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. J Biomol Screen. 2014 Jun 6. pii: 1087057114537378. [PMID 24907126] Intellectual Property: HHS Reference No. E–294–2009/0— • US Patent Application No. 13/ 810,774 filed 17 Jan 2013 • EP Patent Application No. 11741023.3 filed 19 July 2011 Related Technology: HHS Reference No. E–148–2011/0—PCT Patent Application No. PCT/US2013070156 filed 14 Nov 2013, entitled ‘‘Tocopherol and Tocopheryl Quinone Derivatives as Correctors of Lysosomal Storage Disorders.’’ Licensing Contact: Suryanarayana Vepa, Ph.D., J.D.; 301–435–5020; vepas@mail.nih.gov. Collaborative Research Opportunity: The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize particular therapeutic uses of delta tocopherol. Please contact Dr. Wei Zheng at wzheng@mail.nih.gov for more information. 18F-Labeled Calcofluor Derivatives for PET Imaging and Diagnosis of Aspergillus Infection Description of Technology: Aspergillus is a common fungal lung infection with high mortality rates in immune compromised patients. The inability to diagnose this infection impedes treatment. Blood based diagnostic tests for this infection lack sensitivity and specificity due to cross reactivity. Other methods of diagnosis are invasive and labor intensive. The ability to accurately and non-invasively diagnose infection in Aspergillus immune compromised populations may greatly improve treatment and lower mortality rates. This technology uses 18F-labeled calcofluor derivatives for positron emission tomography (PET) imaging of filamentous fungal infections. 18F-labeled calcofluor derivatives have low toxicity, high binding specificity to Aspergillus species due to uptake by Aspergillusspecific siderphore system, and low binding affinity to patient tissue. These compounds may be used for rapid and PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 40121 accurate PET diagnostic imaging of infection by species of Aspergillus. Potential Commercial Applications: Diagnosis of Aspergillus infection. Competitive Advantages: Noninvasive, low toxicity, specific for Aspergillus. Development Stage: In vivo data available (animal). Inventors: Peter Williamson (NIAID), John Panepinto (Univ. Buffalo), Dale Kiesewetter (NIBIB), Jin Qui (NIAID). Publications: 1. Palmer GE, et al. The diverse roles of autophagy in medically important fungi. Autophagy. 2008 Nov;4(8):982–8. [PMID 18927489] 2. Panepinto JC, et al. Deletion of the Aspergillus fumigatus gene encoding the Ras-related protein RhbA reduces virulence in a model of invasive pulmonary aspergillosis. Infect Immun. 2003 May;71(5):2819–26. [PMID 12704156] 3. Desoubeaux D, et al., Diagnosis of invasive pulmonary aspergillosis: Updates and recommendations, Med Mal Infect. 2014 Mar; 44(3):89–101. [PMID 24548415] Intellectual Property: HHS Reference No. E–449–201/0—US Provisional Application No. 61/894,754 filed 23 Oct 2013. Licensing Contact: Edward (Tedd) Fenn; 424–297–0336; Tedd.fenn@ nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Nadine Chien at 301–827–0258. Multifunctional RNA Nanoparticles as Therapeutic Agents Description of Technology: The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present invention discloses novel RNA and RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. These RNA nanoparticles are useful for various nanotechnological applications. This technology has a higher detection sensitivity and higher silencing efficiencies of targeted genes than conventional siRNAs. This technology has significant therapeutic potential against multiple disease types, including cancer and viral infections. Potential Commercial Applications: • Treatment for various diseases E:\FR\FM\11JYN1.SGM 11JYN1 40122 Federal Register / Vol. 79, No. 133 / Friday, July 11, 2014 / Notices • Clinical research • Basic research Competitive Advantages: • More sensitivity • Higher efficiency • Low cytotoxicity • Multiple functionality • Multiple targets • Visualization • Controlled activation Development Stage: • In vitro data available • In vivo data available Inventors: Bruce A. Shapiro, Kirill A. Afonin, Angelica N. Martins, Mathias D. Viard (all of NCI) Intellectual Property: HHS Reference No. E–765–2013/0—US Provisional Application No. 61/878,758 filed 17 Sep 2013. Related Technologies: • HHS Reference No. E–039–2012 • HHS Reference No. E–156–2014 Licensing Contact: John Stansberry, Ph.D.; 301–435–5236; stansbej@ mail.nih.gov Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize scaling up, animal models, multiple targets, delivery. For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewesj@ mail.nih.gov. tkelley on DSK3SPTVN1PROD with NOTICES Nucleic Acid Nanoparticles for Triggering RNA Interference Description of Technology: RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases. The present invention discloses RNA, RNA–DNA, DNA–RNA, hybrid nanocubes consisting of a DNA or RNA core (composed of six strands) with attached RNA or DNA hybrid duplexes. The nanocubes can induce the reassociation of the RNA duplexes, which can then be processed by the human recombinant Dicer enzyme, thus activating RNAi. This technology opens a new route for the development of ‘‘smart’’ nucleic acid based nanoparticles for a wide range of biomedical applications. Immune responses can be controlled by altering the composition of the particles. Potential Commercial Applications: • Treatment for various diseases • Clinical research VerDate Mar<15>2010 20:23 Jul 10, 2014 Jkt 232001 • Basic research Competitive Advantages: • Low cytotoxicity • Chemical stability • More specificity • Controlled activation • Multiple targets • Visualization Development Stage: In vitro data available Inventors: Bruce A. Shapiro, Kirill A. Afonin, Mathias D. Viard (all of NCI) Publications: 1. Afonin KA, et al. Computational and experimental characterization of RNA cubic nanoscaffolds. Methods. 2014 May 15;67(2):256–65. [PMID 24189588] 2. Afonin KA, et al. In vitro assembly of cubic RNA-based scaffolds designed in silico. Nat Nanotechnol. 2010 Sep;5(9):676–82. [PMID 20802494] Intellectual Property: HHS Reference No. E–156–2014/0—US Provisional Application 61/989,520 filed 06 May 2014 Related Technologies: • HHS Reference No. E–765–2013 • HHS Reference No. E–039–2012 Licensing Contact: John Stansberry, Ph.D.; 301–435–5236; stansbej@ mail.nih.gov Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize scaling up, animal models, multiple targets, delivery. For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewesj@ mail.nih.gov. Dated: July 10, 2014. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2014–16265 Filed 7–10–14; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health National Institute of Environmental Health Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial Frm 00065 Fmt 4703 Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel,Pathway to Independence Awards. Date: August 6, 2014. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Environmental Health Sciences, Keystone Building, Conference Room 1002, 530 Davis Drive, Research Triangle Park, NC 27709, (Telephone Conference Call). Contact Person: Leroy Worth, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P. O. Box 12233, MD EC– 30/Room 3171, Research Triangle Park, NC 27709, (919) 541–0670, worth@niehs.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS). Dated: July 8, 2014. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–16260 Filed 7–10–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Sfmt 4703 National Institute of General Medical Sciences; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. E:\FR\FM\11JYN1.SGM 11JYN1

Agencies

[Federal Register Volume 79, Number 133 (Friday, July 11, 2014)]
[Notices]
[Pages 40120-40122]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-16265]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the Office of Technology Transfer, 
National Institutes of Health, 6011 Executive

[[Page 40121]]

Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-
496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Delta Tocopherol for the Treatment of Lysosomal Storage Disorders

    Description of Technology: Delta Tocopherol is identified as a 
novel therapeutic to treat lysosomal disorders characterized by 
defective cellular cholesterol and other lipid trafficking and storage. 
Currently, there is no treatment for many of Lysosomal Storage 
Disorders. In some cases, such as Gaucher disease, enzyme replacement 
therapy and substrate deduction treatment are available with very high 
cost (over $100,000 per patient per year). NIH investigators have 
identified an unexpected and previously unrecognized use for delta 
tocopherol, which is a form of vitamin E, in the treatment of diseases 
and conditions related to lysosomal storage disorders. Scientists at 
the National Center for Advancing Translational Sciences, NIH 
discovered a clear difference between the effects of delta-tocopherol 
and alpha tocopherol on the cell-based disease models of Niemann Pick C 
(NPC) disease. They found that while delta-tocopherol significantly 
reduced the cholesterol accumulation in NPC cells and reduced the size 
of enlarged lysosomes, alpha-tocopherol only showed weak effects in the 
same cells.
    The present invention can be used to develop new therapies 
involving delta-tocopherol to treat lysosomal disorders, such as 
Niemann-Pick type C disease, Mucopolysaccharidoses disorder, and 
Neuronal Ceroid Lipofuscinoses. This invention provides potential novel 
methods for the modulation of cholesterol and other lipids' recycling. 
It may be also possible to use delta-tocopherol for the reduction of 
the size of enlarged lysosomes caused by accumulation of lipids and 
macromolecules.
    Potential Commercial Applications:
     Therapeutics for lysosomal disorders
     Therapeutics for Niemann-Pick type C disease
    Competitive Advantages: delta-tocopherol is a novel lead compound 
for drug development to treat a variety of lysosomal storage diseases 
characterized by lipid/macromolecule accumulation and defective lipid 
trafficking.
    Development Stage:
     Early-stage
     In vitro data available
    Inventors: Wei Zheng et al. (NCATS).
    Publications:

1. Xu M, et al. delta-Tocopherol reduces lipid accumulation in 
Niemann-Pick type C1 and Wolman cholesterol storage disorders. J 
Biol Chem. 2012 Nov 16;287(47):39349-60. [PMID 23035117]
2. Yu D, et al. Niemann-Pick Disease Type C: Induced Pluripotent 
Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and 
Evaluating Drug Efficacy. J Biomol Screen. 2014 Jun 6. pii: 
1087057114537378. [PMID 24907126]

    Intellectual Property: HHS Reference No. E-294-2009/0--
     US Patent Application No. 13/810,774 filed 17 Jan 2013
     EP Patent Application No. 11741023.3 filed 19 July 2011
    Related Technology: HHS Reference No. E-148-2011/0--PCT Patent 
Application No. PCT/US2013070156 filed 14 Nov 2013, entitled 
``Tocopherol and Tocopheryl Quinone Derivatives as Correctors of 
Lysosomal Storage Disorders.''
    Licensing Contact: Suryanarayana Vepa, Ph.D., J.D.; 301-435-5020; 
vepas@mail.nih.gov.
    Collaborative Research Opportunity: The National Center for 
Advancing Translational Sciences is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize particular therapeutic uses of 
delta tocopherol. Please contact Dr. Wei Zheng at wzheng@mail.nih.gov 
for more information.

\18\F-Labeled Calcofluor Derivatives for PET Imaging and Diagnosis of 
Aspergillus Infection

    Description of Technology: Aspergillus is a common fungal lung 
infection with high mortality rates in immune compromised patients. The 
inability to diagnose this infection impedes treatment. Blood based 
diagnostic tests for this infection lack sensitivity and specificity 
due to cross reactivity. Other methods of diagnosis are invasive and 
labor intensive. The ability to accurately and non-invasively diagnose 
infection in Aspergillus immune compromised populations may greatly 
improve treatment and lower mortality rates. This technology uses 
\18\F-labeled calcofluor derivatives for positron emission tomography 
(PET) imaging of filamentous fungal infections. \18\F-labeled 
calcofluor derivatives have low toxicity, high binding specificity to 
Aspergillus species due to uptake by Aspergillus-specific siderphore 
system, and low binding affinity to patient tissue. These compounds may 
be used for rapid and accurate PET diagnostic imaging of infection by 
species of Aspergillus.
    Potential Commercial Applications: Diagnosis of Aspergillus 
infection.
    Competitive Advantages: Non-invasive, low toxicity, specific for 
Aspergillus.
    Development Stage: In vivo data available (animal).
    Inventors: Peter Williamson (NIAID), John Panepinto (Univ. 
Buffalo), Dale Kiesewetter (NIBIB), Jin Qui (NIAID).
    Publications:

1. Palmer GE, et al. The diverse roles of autophagy in medically 
important fungi. Autophagy. 2008 Nov;4(8):982-8. [PMID 18927489]
2. Panepinto JC, et al. Deletion of the Aspergillus fumigatus gene 
encoding the Ras-related protein RhbA reduces virulence in a model 
of invasive pulmonary aspergillosis. Infect Immun. 2003 
May;71(5):2819-26. [PMID 12704156]
3. Desoubeaux D, et al., Diagnosis of invasive pulmonary 
aspergillosis: Updates and recommendations, Med Mal Infect. 2014 
Mar; 44(3):89-101. [PMID 24548415]

    Intellectual Property: HHS Reference No. E-449-201/0--US 
Provisional Application No. 61/894,754 filed 23 Oct 2013.
    Licensing Contact: Edward (Tedd) Fenn; 424-297-0336; 
Tedd.fenn@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this technology. For collaboration 
opportunities, please contact Nadine Chien at 301-827-0258.

Multifunctional RNA Nanoparticles as Therapeutic Agents

    Description of Technology: The promise of RNA interference based 
therapeutics is made evident by the recent surge of biotechnological 
drug companies that pursue such therapies and their progression into 
human clinical trials. The present invention discloses novel RNA and 
RNA/DNA nanoparticles including multiple siRNAs, RNA aptamers, 
fluorescent dyes, and proteins. These RNA nanoparticles are useful for 
various nanotechnological applications. This technology has a higher 
detection sensitivity and higher silencing efficiencies of targeted 
genes than conventional siRNAs. This technology has significant 
therapeutic potential against multiple disease types, including cancer 
and viral infections.
    Potential Commercial Applications:
     Treatment for various diseases

[[Page 40122]]

     Clinical research
     Basic research
    Competitive Advantages:
     More sensitivity
     Higher efficiency
     Low cytotoxicity
     Multiple functionality
     Multiple targets
     Visualization
     Controlled activation
    Development Stage:
     In vitro data available
     In vivo data available
    Inventors: Bruce A. Shapiro, Kirill A. Afonin, Angelica N. Martins, 
Mathias D. Viard (all of NCI)
    Intellectual Property: HHS Reference No. E-765-2013/0--US 
Provisional Application No. 61/878,758 filed 17 Sep 2013.
    Related Technologies:
     HHS Reference No. E-039-2012
     HHS Reference No. E-156-2014
    Licensing Contact: John Stansberry, Ph.D.; 301-435-5236; 
stansbej@mail.nih.gov
    Collaborative Research Opportunity: The National Cancer Institute 
is seeking statements of capability or interest from parties interested 
in collaborative research to further develop, evaluate or commercialize 
scaling up, animal models, multiple targets, delivery. For 
collaboration opportunities, please contact John D. Hewes, Ph.D. at 
hewesj@mail.nih.gov.

Nucleic Acid Nanoparticles for Triggering RNA Interference

    Description of Technology: RNA interference (RNAi) is a naturally 
occurring cellular post-transcriptional gene regulation process that 
utilizes small double-stranded RNAs to trigger and guide gene 
silencing. By introducing synthetic RNA duplexes called small-
interfering RNAs (siRNAs), we can harness the RNAi machinery for 
therapeutic gene control and the treatment of various diseases.
    The present invention discloses RNA, RNA-DNA, DNA-RNA, hybrid 
nanocubes consisting of a DNA or RNA core (composed of six strands) 
with attached RNA or DNA hybrid duplexes. The nanocubes can induce the 
reassociation of the RNA duplexes, which can then be processed by the 
human recombinant Dicer enzyme, thus activating RNAi. This technology 
opens a new route for the development of ``smart'' nucleic acid based 
nanoparticles for a wide range of biomedical applications. Immune 
responses can be controlled by altering the composition of the 
particles.
    Potential Commercial Applications:
     Treatment for various diseases
     Clinical research
     Basic research
    Competitive Advantages:
     Low cytotoxicity
     Chemical stability
     More specificity
     Controlled activation
     Multiple targets
     Visualization
    Development Stage: In vitro data available
    Inventors: Bruce A. Shapiro, Kirill A. Afonin, Mathias D. Viard 
(all of NCI)
    Publications:
    1. Afonin KA, et al. Computational and experimental 
characterization of RNA cubic nanoscaffolds. Methods. 2014 May 
15;67(2):256-65. [PMID 24189588]
    2. Afonin KA, et al. In vitro assembly of cubic RNA-based 
scaffolds designed in silico. Nat Nanotechnol. 2010 Sep;5(9):676-82. 
[PMID 20802494]

    Intellectual Property: HHS Reference No. E-156-2014/0--US 
Provisional Application 61/989,520 filed 06 May 2014
    Related Technologies:
     HHS Reference No. E-765-2013
     HHS Reference No. E-039-2012
    Licensing Contact: John Stansberry, Ph.D.; 301-435-5236; 
stansbej@mail.nih.gov
    Collaborative Research Opportunity: The National Cancer Institute 
is seeking statements of capability or interest from parties interested 
in collaborative research to further develop, evaluate or commercialize 
scaling up, animal models, multiple targets, delivery. For 
collaboration opportunities, please contact John D. Hewes, Ph.D. at 
hewesj@mail.nih.gov.

    Dated: July 10, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-16265 Filed 7-10-14; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.